Safety Evaluation and Anti-Inflammatory Efficacy of Lacticaseibacillus paracasei PS23

Chin Hao Li, Tai Ying Chen, Chien Chen Wu, Shih Hsuan Cheng, Min Yu Chang, Wei Hong Cheng, Shih Hau Chiu, Chien Chi Chen, Ying Chieh Tsai, Deng Jye Yang, Jaw Jou Kang, Po Lin Liao*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Lacticaseibacillus paracasei strain PS23 (PS23) exhibits some probiotic properties. In this study, a genomic analysis of PS23 revealed no genes related to virulence or antibiotic resistance. Moreover, ornithine decarboxylase activity was not detected in vitro. In addition, PS23 was sensitive to the tested antibiotics. Genotoxicity tests for PS23 including the Ames test and chromosomal aberrations in vitro using Chinese hamster ovary cells and micronuclei in immature erythrocytes of ICR mice were all negative. Moreover, following a 28-day study involving repeated oral dose toxicity tests (40, 400, and 4000 mg/kg equal 1.28 × 1010, 1.28 × 1011, and 1.28 × 1012 CFU/kg body weight, respectively) using an ICR mouse model, no adverse effects were observed from any doses. In addition, supplementation with live or heat-killed PS23 ameliorates DSS-induced colonic inflammation in mice. Our findings suggest that PS23 is safe and has anti-inflammatory effects and may therefore have therapeutic implications.

Original languageEnglish
Article number724
JournalInternational Journal Of Molecular Sciences
Issue number1
StatePublished - Jan 2023


  • 28-day repeated oral dose toxicity
  • genome-based safety assessment
  • genotoxicity test
  • Lacticaseibacillus paracasei PS23
  • no observed adverse effect level


Dive into the research topics of 'Safety Evaluation and Anti-Inflammatory Efficacy of Lacticaseibacillus paracasei PS23'. Together they form a unique fingerprint.

Cite this